OptiBiotix Health Plc (OPTI) - Total Liabilities
Based on the latest financial reports, OptiBiotix Health Plc (OPTI) has total liabilities worth GBX732.00K GBX (≈ $89.06 USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore OptiBiotix Health Plc long-term investment allocation to see how much of total assets are deployed in long-term investments.
OptiBiotix Health Plc - Total Liabilities Trend (2008–2024)
This chart illustrates how OptiBiotix Health Plc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see OptiBiotix Health Plc balance sheet assets.
OptiBiotix Health Plc Competitors by Total Liabilities
The table below lists competitors of OptiBiotix Health Plc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eneraqua Technologies PLC
LSE:ETP
|
UK | GBX23.55 Million |
|
Blackbird PLC
LSE:BIRD
|
UK | GBX677.08K |
|
Transense Technologies PLC
LSE:TRT
|
UK | GBX1.24 Million |
|
Digitalbox PLC
LSE:DBOX
|
UK | GBX366.00K |
|
Getech Group
LSE:GTC
|
UK | GBX3.11 Million |
|
EARNZ plc
LSE:EARN
|
UK | GBX4.48 Million |
|
Kasikornbank Public Company Limited
F:TFBF
|
Germany | €3.90 Trillion |
Liability Composition Analysis (2008–2024)
This chart breaks down OptiBiotix Health Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See OPTI net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how OptiBiotix Health Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for OptiBiotix Health Plc (2008–2024)
The table below shows the annual total liabilities of OptiBiotix Health Plc from 2008 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX647.00K ≈ $78.72 |
+21.62% |
| 2023-12-31 | GBX532.00K ≈ $64.73 |
-17.26% |
| 2022-12-31 | GBX643.00K ≈ $78.23 |
-67.40% |
| 2021-12-31 | GBX1.97 Million ≈ $239.97 |
+6.48% |
| 2020-12-31 | GBX1.85 Million ≈ $225.37 |
+2.29% |
| 2019-12-31 | GBX1.81 Million ≈ $220.32 |
+87.23% |
| 2018-11-30 | GBX967.15K ≈ $117.67 |
+55.12% |
| 2017-11-30 | GBX623.49K ≈ $75.86 |
-5.60% |
| 2016-11-30 | GBX660.49K ≈ $80.36 |
+18.99% |
| 2015-11-30 | GBX555.10K ≈ $67.54 |
+4.84% |
| 2014-11-30 | GBX529.49K ≈ $64.42 |
+185.38% |
| 2013-11-30 | GBX185.53K ≈ $22.57 |
-53.55% |
| 2012-07-31 | GBX399.46K ≈ $48.60 |
+3531.47% |
| 2010-07-31 | GBX11.00K ≈ $1.34 |
-8.33% |
| 2009-07-31 | GBX12.00K ≈ $1.46 |
-76.47% |
| 2008-07-31 | GBX51.00K ≈ $6.21 |
-- |
About OptiBiotix Health Plc
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential… Read more